AstraZeneca's shot, among the cheapest available, was billed as the vaccine of choice for poorer nations and the clot reports have had an impact beyond Europe.
As Covid infection rates hit record highs, the government is pinning its hopes on the Oxford/AstraZeneca jab, which is cheaper to produce, and easier to store and transport.